STAT3 and lung carcinoma: Additionally, several other molecules and signaling pathways that target TAMs have been identified in lung cancer, such as TCF21 (129), ADPGK-AS1 (137), TLR4 (138) and JMJD6/STAT3/IL-10 (139), which are also considered potential targets for immunotherapy.